MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027

Lifesciences | Pharmaceuticals

MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027

Market By Dosages, Formulation And Geography | Forecast 2019-2027

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

Triton's report on the hyperphosphatemia drugs market in the Middle East and Africa states that the market is expected to grow with a CAGR of 18.96% in the forecast period 2019-2027.

The report on the Middle East and Africa hyperphosphatemia drugs market includes the countries of:

•           Saudi Arabia

•           Turkey

•           United Arab Emirates

•           South Africa

•           Rest of Middle East & Africa

Report scope can be customized per your requirements. Request For Customization

The Middle East and Africa region is a superior growth region for the hyperphosphatemia drugs market as rising occurrences of hyperphosphatemia cases across the area have been observed due to the unhealthy and extremely untidy lifestyles. Furthermore, there is huge illiteracy in the region, which is a key driving factor for this ailment being prevalent in the area. Higher illiteracy rate leaves people with unhealthy living practices devoid of basic sanitation activities, along with the expanding population in the region creating a vicious cycle. Several major factors are driving viable, lasting growth across the sector throughout the region that includes elevated maternal mortality rate driven by unhealthy lifestyle, high consumption of meat, improving medical facilities and expanding chances of obstetric problems. Moreover, impressive government subsidies and key promotional activities of the government are believed to drive the sustainable long-term growth of hyperphosphatemia drugs, thus assisting people to overcome, heal and finally eradicate the menace of hyperphosphatemia in the region.

Hyperphosphatemia, which means raised phosphate levels, is related to the development of vascular calcification and cardiovascular disease. The major application of hyperphosphatemia drugs is in reducing phosphate levels. One of the primary drugs used in reducing phosphate level is calcium acetate, which is a phosphate binder. It works by avoiding phosphate in the intestines and stomach from being absorbed into the body. Some other drugs used are Phoslo and Renege. These drugs are applicable in lowering high blood phosphate in patients those are on dialysis due to severe kidney disease. FDA regulations are strict for hyperphosphatemia drugs. There has been a high focus by the FDA on these drugs, and have especially focused on their effectiveness. The FDA requires a specification for new drugs on hyperphosphatemia.

 

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER’S FIVE FORCE MODEL

2.2.1.   THREAT OF NEW ENTRANTS

2.2.2.   BARGAINING POWER OF BUYERS

2.2.3.   BARGAINING POWER OF SUPPLIERS

2.2.4.   THREAT OF SUBSTITUTE PRODUCT

2.2.5.   INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. KEY BUYING OUTLOOK

2.5. KEY INSIGHTS

2.6. KEY MARKET TRENDS

2.7. GUIDELINES RELATED TO THE PHOSPHATE BINDERS

2.8. MARKET DRIVERS

2.8.1.   CHRONIC DISORDERS ARE INCREASING RAPIDLY

2.8.2.   INCREASE IN PUBLIC COGNIZANCE

2.8.3.   INCREASE IN GERIATRIC POPULATION

2.9. MARKET RESTRAINTS

2.9.1.   SIDE-EFFECTS RELATED TO THE USAGE OF HYPERPHOSPHATEMIA DRUGS

2.9.2.   STRICT FOOD AND DRUG ADMINISTRATION (FDA) REGULATIONS

2.10.            MARKET OPPORTUNITIES

2.10.1.                RISE IN THE AGING POPULATION

2.11.            MARKET CHALLENGES

2.11.1.                ALTERNATIVE DIALYSIS TECHNIQUES

2.11.2.                ACCESSIBILITY OF DRUGS IS LIMITED

2.11.3.                NON-ADHERENCE TO TREATMENT REGIMES

3.    HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK - BY DOSAGES

3.1. SOLID

3.1.1.   TABLET

3.1.2.   POWDER

3.2. LIQUID

3.2.1.   SOLUTION

4.    HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK - BY FORMULATION

4.1.1.   CALCIUM-BASED PHOSPHATE BINDERS

4.1.2.   ALUMINUM-BASED PHOSPHATE BINDERS

4.1.3.   MAGNESIUM-BASED PHOSPHATE BINDERS

4.1.4.   IRON-BASED PHOSPHATE BINDERS

4.1.5.   OTHER PHOSPHATE BINDERS

5.    HYPERPHOSPHATEMIA DRUGS MARKET - REGIONAL OUTLOOK

5.1. MIDDLE EAST AND AFRICA

5.1.1.   COUNTRY ANALYSIS

5.1.1.1.      SAUDI ARABIA

5.1.1.2.      TURKEY

5.1.1.3.      UNITED ARAB EMIRATES

5.1.1.4.      SOUTH AFRICA

5.1.1.5.      REST OF MIDDLE EAST & AFRICA

6.    COMPETITIVE LANDSCAPE

6.1. JOHNSON AND JOHNSON

6.2. ZERIA PHARMACEUTICAL

6.3. AMAG PHARMACEUTICALS

6.4. SANOFI

6.5. BRUNO FARMACEUTICI S.P.A.

6.6. ROCHE DIAGNOSTICS CORPORATION

6.7. ROYAL DSM N.V.

6.8. SHIRE

6.9. CIPLA

6.10.            ULTRAGENYX PHARMACEUTICAL, INC.

6.11.            FERMENTA BIOTECH, LTD.

6.12.            BIOTECH PHARMACAL

6.13.            SUN PHARMACEUTICAL INDUSTRIES, LTD.

6.14.            KERYX BIOPHARMACEUTICALS, INC.

6.15.            FRESENIUS MEDICAL CARE

6.16.            PFIZER, INC.

7.    METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE

7.2. SOURCES OF DATA

7.3. RESEARCH METHODOLOGY

List of table

TABLE 1        MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

TABLE 2        PHOSPHORUS LEVELS IN SELECT FOODS

TABLE 3        MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 ($ MILLION)

TABLE 4        DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

TABLE 5        MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 ($ MILLION)        

 

List of Figures

FIGURE 1      PORTER’S FIVE FORCES MODEL OF HYPERPHOSPHATEMIA DRUGS MARKET

FIGURE 2      IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017

FIGURE 3      RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE 4      MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 5      MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 6      MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 7      MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 8      MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 9      MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET SHARE 2018 & 2027 (%)

FIGURE 10   MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 11   SAUDI ARABIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 12   TURKEY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 13   UNITED ARAB EMIRATES HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 14   SOUTH AFRICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 15   REST OF MIDDLE EAST & AFRICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;